“Would you be surprised?” Using the Surprise Question to Explore Medication Discontinuation

1 Study Overview

1.1 Background

The surprise question was developed over a decade ago and has been used in multiple settings to predict one year survival of different patient populations (e.g., to identify older hospitalized patients who may benefit from palliative or hospice care, to identify patients in the ED with a high risk of in-hospital mortality, predicting mortality for dialysis patients). The surprise question simply asks healthcare providers “would you be surprised if the patient died in the next 12 months?” No additional clinical data is needed. The predictive value of the surprise question has ranged from poor to reasonably accurate.

This quality improvement project would be to pilot the “surprise question” in select specialty clinics to assess its prognostic value in predicting patient outcomes. In Asthma and Allergy (ASAP) and Dermatology, pharmacists answered the question “Would you be surprised if this patient had a PDC of less than 90 or dose interruptions totaling 28 days or more over the next 6 months?”. In Oncology and Neurology, pharmacists answered the question “Would you be surprised if this patient discontinued this medication in the next 90 days?”

1.2 Methods

Quality Improvement Pilot.

2 Exclusions

Characteristic N Overall
N = 1,611
1
ASAP
N = 292
1
Dermatology
N = 317
1
Neurology
N = 201
1
Oncology
N = 801
1
Inclusion status 1,611




    Excluded
304 (18.9%) 57 (19.5%) 64 (20.2%) 25 (12.4%) 158 (19.7%)
    Included
1,307 (81.1%) 235 (80.5%) 253 (79.8%) 176 (87.6%) 643 (80.3%)
Exclusion reason 304




    ASAP/Derm patients with <3 fills or with documented discontinuation
41 (13.5%) 18 (31.6%) 23 (35.9%) 0 (0%) 0 (0%)
    Mediation had a finite duration known at therapy initiation
66 (21.7%) 0 (0%) 1 (1.56%) 0 (0%) 65 (41.1%)
    Medically appropriate hold
1 (0.33%) 1 (1.75%) 0 (0%) 0 (0%) 0 (0%)
    Medication dosed as needed
5 (1.64%) 5 (8.77%) 0 (0%) 0 (0%) 0 (0%)
    Medication never started
31 (10.2%) 5 (8.77%) 9 (14.1%) 3 (12.0%) 14 (8.86%)
    Prescription fill data was not available
24 (7.89%) 4 (7.02%) 6 (9.38%) 5 (20.0%) 9 (5.70%)
    Surprise question not answered or duplicate
136 (44.7%) 24 (42.1%) 25 (39.1%) 17 (68.0%) 70 (44.3%)
1 n (%)

3 Demographics

Patient-medication level

Characteristic Overall
N = 1,307
1
ASAP
N = 235
1
Dermatology
N = 253
1
Neurology
N = 176
1
Oncology
N = 643
1
Age at date counseled




    Mean (SD) 55.7 (21.6) 38.6 (25.8) 46.5 (21.3) 62.9 (18.6) 63.6 (14.7)
    Median (Q1, Q3) 62.0 (41.9, 72.4) 40.3 (12.2, 63.3) 47.2 (29.9, 64.2) 67.4 (55.9, 75.4) 67.0 (55.4, 74.1)
    Min, Max 0.4, 92.3 0.5, 91.9 1.1, 92.3 0.4, 91.6 15.8, 92.1
Sex




    Female 633 (48.4%) 146 (62.1%) 154 (60.9%) 75 (42.6%) 258 (40.1%)
    Male 673 (51.5%) 89 (37.9%) 98 (38.7%) 101 (57.4%) 385 (59.9%)
    Unknown 1 (0.08%) 0 (0%) 1 (0.40%) 0 (0%) 0 (0%)
Race




    White 1,040 (79.6%) 168 (71.5%) 182 (71.9%) 140 (79.5%) 550 (85.5%)
    Black or African American 166 (12.7%) 41 (17.4%) 39 (15.4%) 23 (13.1%) 63 (9.80%)
    Other 61 (4.67%) 15 (6.38%) 15 (5.93%) 10 (5.68%) 21 (3.27%)
    Unknown 40 (3.06%) 11 (4.68%) 17 (6.72%) 3 (1.70%) 9 (1.40%)
1 n (%)

Patient level, but one patient represented twice Derm + Onc

Characteristic Overall
N = 1,229
1
ASAP
N = 234
1
Dermatology
N = 252
1
Neurology
N = 165
1
Oncology
N = 578
1
Age at date counseled




    Mean (SD) 55.2 (21.8) 38.5 (25.7) 46.6 (21.3) 63.3 (18.4) 63.4 (14.6)
    Median (Q1, Q3) 61.5 (41.5, 72.3) 40.3 (12.2, 63.3) 47.4 (30.2, 64.2) 68.2 (55.4, 76.0) 66.9 (55.1, 73.9)
    Min, Max 0.4, 92.3 0.5, 91.9 1.1, 92.3 0.4, 91.6 15.8, 92.1
Sex




    Female 611 (49.7%) 146 (62.4%) 153 (60.7%) 71 (43.0%) 241 (41.7%)
    Male 617 (50.2%) 88 (37.6%) 98 (38.9%) 94 (57.0%) 337 (58.3%)
    Unknown 1 (0.08%) 0 (0%) 1 (0.40%) 0 (0%) 0 (0%)
Race




    White 970 (78.9%) 167 (71.4%) 181 (71.8%) 130 (78.8%) 492 (85.1%)
    Black or African American 159 (12.9%) 41 (17.5%) 39 (15.5%) 22 (13.3%) 57 (9.86%)
    Other 60 (4.88%) 15 (6.41%) 15 (5.95%) 10 (6.06%) 20 (3.46%)
    Unknown 40 (3.25%) 11 (4.70%) 17 (6.75%) 3 (1.82%) 9 (1.56%)
1 n (%)

4 Background Information: Breakdown on Specialty medication by clinical area

4.1 Neurology

Characteristic1 N1 N = 1761
Medication 176
    Droxidopa
48 (27.3%)
    Pimavanserin
19 (10.8%)
    Edaravone
16 (9.09%)
    Cannabidiol
13 (7.39%)
    Riluzole
11 (6.25%)
    Deutetrabenazine
10 (5.68%)
    Tafamidis
9 (5.11%)
    Valbenazine
8 (4.55%)
    Acoramidis
7 (3.98%)
    Eplontersen Sodium
7 (3.98%)
    Amantadine
6 (3.41%)
    Amantadine HCl ER
6 (3.41%)
    Deutetrabenazine ER
6 (3.41%)
    Tetrabenazine
5 (2.84%)
    Istradefylline
2 (1.14%)
    Vigabatrin
2 (1.14%)
    Adalimumab
1 (0.57%)
1 176 medications among 165 patients

4.2 Oncology

Characteristic1 N1 N = 6431
Medication 643
    Relugolix
119 (18.5%)
    Capecitabine
40 (6.22%)
    Abiraterone Acetate
37 (5.75%)
    Temozolomide
33 (5.13%)
    Venetoclax
29 (4.51%)
    Darolutamide
22 (3.42%)
    Ribociclib
20 (3.11%)
    Eltrombopag Olamine
16 (2.49%)
    Decitabine-Cedazuridine
15 (2.33%)
    Ruxolitinib Phosphate
15 (2.33%)
    Abemaciclib
13 (2.02%)
    Asciminib HCl
13 (2.02%)
    Lenvatinib
13 (2.02%)
    Palbociclib
12 (1.87%)
    Zanubrutinib
12 (1.87%)
    Belumosudil Mesylate
8 (1.24%)
    Cabozantinib S-Malate
8 (1.24%)
    Capivasertib
8 (1.24%)
    Dasatinib
8 (1.24%)
    PAZOPanib
8 (1.24%)
    Cabozantinib
7 (1.09%)
    Everolimus
7 (1.09%)
    Imatinib Mesylate
7 (1.09%)
    Osimertinib Mesylate
7 (1.09%)
    Enzalutamide
6 (0.93%)
    Lomustine
6 (0.93%)
    Momelotinib Dihydrochloride
6 (0.93%)
    Nirogacestat
6 (0.93%)
    Pirtobrutinib
6 (0.93%)
    Acalabrutinib
5 (0.78%)
    Adagrasib
5 (0.78%)
    Deferasirox
5 (0.78%)
    Ropeginterferon alfa-2b-njft
5 (0.78%)
    Trifluridine-Tipiracil
5 (0.78%)
    Axitinib
4 (0.62%)
    Belzutifan
4 (0.62%)
    cycloPHOSphamide
4 (0.62%)
    Encorafenib
4 (0.62%)
    Lorlatinib
4 (0.62%)
    PONATinib HCl
4 (0.62%)
    SUNItinib Malate
4 (0.62%)
    Trametinib Dimethyl Sulfoxide
4 (0.62%)
    Vorasidenib
4 (0.62%)
    Apalutamide
3 (0.47%)
    Binimetinib
3 (0.47%)
    Dabrafenib Mesylate
3 (0.47%)
    Deferiprone
3 (0.47%)
    Ivosidenib
3 (0.47%)
    Ixazomib Citrate
3 (0.47%)
    Olaparib
3 (0.47%)
    Tivozanib HCl
3 (0.47%)
    Tretinoin
3 (0.47%)
    Alectinib HCl
2 (0.31%)
    azaCITIDine
2 (0.31%)
    Bosutinib
2 (0.31%)
    Brigatinib
2 (0.31%)
    Cyclophosphamide
2 (0.31%)
    Erlotinib
2 (0.31%)
    Ibrutinib
2 (0.31%)
    Lazertinib Mesylate
2 (0.31%)
    Midostaurin
2 (0.31%)
    Olutasidenib
2 (0.31%)
    Procarbazine HCl
2 (0.31%)
    Repotrectinib
2 (0.31%)
    Revumenib Citrate
2 (0.31%)
    Ripretinib
2 (0.31%)
    Adalimumab
1 (0.16%)
    Alectinib
1 (0.16%)
    Alpelisib
1 (0.16%)
    Anakinra
1 (0.16%)
    Crizotinib
1 (0.16%)
    Enasidenib Mesylate
1 (0.16%)
    Fostamatinib Disodium
1 (0.16%)
    Futibatinib (20 MG Daily Dose)
1 (0.16%)
    Gilteritinib Fumarate
1 (0.16%)
    Inavolisib
1 (0.16%)
    Larotrectinib Sulfate
1 (0.16%)
    Lenvatinib (4 MG Daily Dose)
1 (0.16%)
    Leuprolide Acetate
1 (0.16%)
    Neratinib
1 (0.16%)
    Pacritinib Citrate
1 (0.16%)
    Selinexor (60 MG Once Weekly)
1 (0.16%)
    SORAfenib Tosylate
1 (0.16%)
    Sotorasib Tosylate
1 (0.16%)
    Telotristat
1 (0.16%)
    Tucatinib
1 (0.16%)
1 643 medications among 578 patients

4.3 ASAP

Characteristic1 N1 N = 2351
Medication 235
    Dupilumab
167 (71.1%)
    Omalizumab
42 (17.9%)
    Tezepelumab-ekko
14 (5.96%)
    Mepolizumab
6 (2.55%)
    Benralizumab
3 (1.28%)
    Peanut Powder-dnfp Starter Pak
2 (0.85%)
    Peanut
1 (0.43%)
1 235 medications among 234 patients

4.4 Dermatology

Characteristic1 N1 N = 2531
Medication 253
    Dupilumab
111 (43.9%)
    Risankizumab-rzaa
34 (13.4%)
    Adalimumab
21 (8.30%)
    Secukinumab
15 (5.93%)
    Apremilast
14 (5.53%)
    Ixekizumab
8 (3.16%)
    Tralokinumab-ldrm
8 (3.16%)
    Upadacitinib
6 (2.37%)
    Upadacitinib ER
6 (2.37%)
    Ustekinumab
6 (2.37%)
    Deucravacitinib
4 (1.58%)
    Etanercept
4 (1.58%)
    Guselkumab
4 (1.58%)
    Ritlecitinib Tosylate
3 (1.19%)
    Baricitinib
2 (0.79%)
    Bexarotene
2 (0.79%)
    Bimekizumab-bkzx
2 (0.79%)
    Golimumab
1 (0.40%)
    Lebrikizumab-lbkz
1 (0.40%)
    Spesolimab-sbzo
1 (0.40%)
1 253 medications among 252 patients

5 Observed outcome summaries

5.1 Neurology

Characteristic Did not dicontinue within 90 days
N = 140
1
Discontinued within 90 days
N = 36
1
Age at date counseled

    Mean (SD) 63 (18) 64 (20)
    Median (Q1, Q3) 67 (54, 75) 69 (60, 76)
    Min, Max 0, 88 6, 92
Race

    White 111 (79.3%) 29 (20.7%)
    Black or African American 20 (87.0%) 3 (13.0%)
    Other 8 (80.0%) 2 (20.0%)
    Unknown 1 (33.3%) 2 (66.7%)
Sex

    Male 81 (80.2%) 20 (19.8%)
    Female 59 (78.7%) 16 (21.3%)
Medication

    Droxidopa 38 (79.2%) 10 (20.8%)
    Pimavanserin 13 (68.4%) 6 (31.6%)
    Edaravone 13 (81.3%) 3 (18.8%)
    Cannabidiol 10 (76.9%) 3 (23.1%)
    Riluzole 11 (100.0%) 0 (0%)
    Deutetrabenazine 9 (90.0%) 1 (10.0%)
    Tafamidis 8 (88.9%) 1 (11.1%)
    Valbenazine 5 (62.5%) 3 (37.5%)
    Acoramidis 7 (100.0%) 0 (0%)
    Eplontersen Sodium 6 (85.7%) 1 (14.3%)
    Amantadine 5 (83.3%) 1 (16.7%)
    Amantadine HCl ER 4 (66.7%) 2 (33.3%)
    Deutetrabenazine ER 5 (83.3%) 1 (16.7%)
    Tetrabenazine 3 (60.0%) 2 (40.0%)
    Istradefylline 1 (50.0%) 1 (50.0%)
    Vigabatrin 2 (100.0%) 0 (0%)
    Adalimumab 0 (0%) 1 (100.0%)
1 n (%)

5.2 Oncology

Characteristic Did not dicontinue within 90 days
N = 505
1
Discontinued within 90 days
N = 138
1
Age at date counseled

    Mean (SD) 63 (15) 64 (15)
    Median (Q1, Q3) 67 (55, 74) 68 (55, 75)
    Min, Max 18, 92 16, 88
Race

    White 432 (78.5%) 118 (21.5%)
    Black or African American 49 (77.8%) 14 (22.2%)
    Other 17 (81.0%) 4 (19.0%)
    Unknown 7 (77.8%) 2 (22.2%)
Sex

    Male 316 (82.1%) 69 (17.9%)
    Female 189 (73.3%) 69 (26.7%)
Medication

    Relugolix 115 (96.6%) 4 (3.36%)
    Capecitabine 28 (70.0%) 12 (30.0%)
    Abiraterone Acetate 32 (86.5%) 5 (13.5%)
    Temozolomide 28 (84.8%) 5 (15.2%)
    Venetoclax 18 (62.1%) 11 (37.9%)
    Darolutamide 20 (90.9%) 2 (9.09%)
    Ribociclib 18 (90.0%) 2 (10.0%)
    Eltrombopag Olamine 8 (50.0%) 8 (50.0%)
    Decitabine-Cedazuridine 9 (60.0%) 6 (40.0%)
    Ruxolitinib Phosphate 15 (100.0%) 0 (0%)
    Abemaciclib 12 (92.3%) 1 (7.69%)
    Asciminib HCl 10 (76.9%) 3 (23.1%)
    Lenvatinib 8 (61.5%) 5 (38.5%)
    Palbociclib 10 (83.3%) 2 (16.7%)
    Zanubrutinib 8 (66.7%) 4 (33.3%)
    Belumosudil Mesylate 8 (100.0%) 0 (0%)
    Cabozantinib S-Malate 4 (50.0%) 4 (50.0%)
    Capivasertib 4 (50.0%) 4 (50.0%)
    Dasatinib 6 (75.0%) 2 (25.0%)
    PAZOPanib 4 (50.0%) 4 (50.0%)
    Cabozantinib 4 (57.1%) 3 (42.9%)
    Everolimus 4 (57.1%) 3 (42.9%)
    Imatinib Mesylate 4 (57.1%) 3 (42.9%)
    Osimertinib Mesylate 6 (85.7%) 1 (14.3%)
    Enzalutamide 5 (83.3%) 1 (16.7%)
    Lomustine 4 (66.7%) 2 (33.3%)
    Momelotinib Dihydrochloride 6 (100.0%) 0 (0%)
    Nirogacestat 5 (83.3%) 1 (16.7%)
    Pirtobrutinib 6 (100.0%) 0 (0%)
    Acalabrutinib 5 (100.0%) 0 (0%)
    Adagrasib 2 (40.0%) 3 (60.0%)
    Deferasirox 4 (80.0%) 1 (20.0%)
    Ropeginterferon alfa-2b-njft 5 (100.0%) 0 (0%)
    Trifluridine-Tipiracil 1 (20.0%) 4 (80.0%)
    Axitinib 4 (100.0%) 0 (0%)
    Belzutifan 3 (75.0%) 1 (25.0%)
    cycloPHOSphamide 3 (75.0%) 1 (25.0%)
    Encorafenib 3 (75.0%) 1 (25.0%)
    Lorlatinib 4 (100.0%) 0 (0%)
    PONATinib HCl 3 (75.0%) 1 (25.0%)
    SUNItinib Malate 2 (50.0%) 2 (50.0%)
    Trametinib Dimethyl Sulfoxide 3 (75.0%) 1 (25.0%)
    Vorasidenib 4 (100.0%) 0 (0%)
    Apalutamide 2 (66.7%) 1 (33.3%)
    Binimetinib 2 (66.7%) 1 (33.3%)
    Dabrafenib Mesylate 2 (66.7%) 1 (33.3%)
    Deferiprone 2 (66.7%) 1 (33.3%)
    Ivosidenib 2 (66.7%) 1 (33.3%)
    Ixazomib Citrate 3 (100.0%) 0 (0%)
    Olaparib 1 (33.3%) 2 (66.7%)
    Tivozanib HCl 2 (66.7%) 1 (33.3%)
    Tretinoin 2 (66.7%) 1 (33.3%)
    Alectinib HCl 2 (100.0%) 0 (0%)
    azaCITIDine 1 (50.0%) 1 (50.0%)
    Bosutinib 2 (100.0%) 0 (0%)
    Brigatinib 2 (100.0%) 0 (0%)
    Cyclophosphamide 1 (50.0%) 1 (50.0%)
    Erlotinib 0 (0%) 2 (100.0%)
    Ibrutinib 0 (0%) 2 (100.0%)
    Lazertinib Mesylate 1 (50.0%) 1 (50.0%)
    Midostaurin 1 (50.0%) 1 (50.0%)
    Olutasidenib 1 (50.0%) 1 (50.0%)
    Procarbazine HCl 1 (50.0%) 1 (50.0%)
    Repotrectinib 2 (100.0%) 0 (0%)
    Revumenib Citrate 2 (100.0%) 0 (0%)
    Ripretinib 1 (50.0%) 1 (50.0%)
    Adalimumab 1 (100.0%) 0 (0%)
    Alectinib 1 (100.0%) 0 (0%)
    Alpelisib 1 (100.0%) 0 (0%)
    Anakinra 0 (0%) 1 (100.0%)
    Crizotinib 1 (100.0%) 0 (0%)
    Enasidenib Mesylate 1 (100.0%) 0 (0%)
    Fostamatinib Disodium 1 (100.0%) 0 (0%)
    Futibatinib (20 MG Daily Dose) 0 (0%) 1 (100.0%)
    Gilteritinib Fumarate 1 (100.0%) 0 (0%)
    Inavolisib 1 (100.0%) 0 (0%)
    Larotrectinib Sulfate 1 (100.0%) 0 (0%)
    Lenvatinib (4 MG Daily Dose) 1 (100.0%) 0 (0%)
    Leuprolide Acetate 1 (100.0%) 0 (0%)
    Neratinib 0 (0%) 1 (100.0%)
    Pacritinib Citrate 1 (100.0%) 0 (0%)
    Selinexor (60 MG Once Weekly) 0 (0%) 1 (100.0%)
    SORAfenib Tosylate 1 (100.0%) 0 (0%)
    Sotorasib Tosylate 1 (100.0%) 0 (0%)
    Telotristat 1 (100.0%) 0 (0%)
    Tucatinib 0 (0%) 1 (100.0%)
1 n (%)

5.3 ASAP

Characteristic PDC greater than or equal to 90
N = 142
1
PDC less than 90
N = 93
1
Age at date counseled

    Mean (SD) 43 (26) 32 (24)
    Median (Q1, Q3) 46 (15, 66) 28 (9, 54)
    Min, Max 3, 92 1, 79
Race

    White 104 (61.9%) 64 (38.1%)
    Black or African American 24 (58.5%) 17 (41.5%)
    Other 6 (40.0%) 9 (60.0%)
    Unknown 8 (72.7%) 3 (27.3%)
Sex

    Female 87 (59.6%) 59 (40.4%)
    Male 55 (61.8%) 34 (38.2%)
Medication

    Dupilumab 101 (60.5%) 66 (39.5%)
    Omalizumab 25 (59.5%) 17 (40.5%)
    Tezepelumab-ekko 8 (57.1%) 6 (42.9%)
    Mepolizumab 4 (66.7%) 2 (33.3%)
    Benralizumab 1 (33.3%) 2 (66.7%)
    Peanut Powder-dnfp Starter Pak 2 (100.0%) 0 (0%)
    Peanut 1 (100.0%) 0 (0%)
1 n (%)
Characteristic At least 1 gap > 28 days
N = 44
1
No gaps > 28 days
N = 191
1
Age at date counseled

    Mean (SD) 35 (24) 39 (26)
    Median (Q1, Q3) 39 (12, 56) 41 (12, 65)
    Min, Max 1, 78 1, 92
Race

    White 26 (15.5%) 142 (84.5%)
    Black or African American 11 (26.8%) 30 (73.2%)
    Other 5 (33.3%) 10 (66.7%)
    Unknown 2 (18.2%) 9 (81.8%)
Sex

    Female 29 (19.9%) 117 (80.1%)
    Male 15 (16.9%) 74 (83.1%)
Medication

    Dupilumab 33 (19.8%) 134 (80.2%)
    Omalizumab 7 (16.7%) 35 (83.3%)
    Tezepelumab-ekko 2 (14.3%) 12 (85.7%)
    Mepolizumab 1 (16.7%) 5 (83.3%)
    Benralizumab 1 (33.3%) 2 (66.7%)
    Peanut Powder-dnfp Starter Pak 0 (0%) 2 (100.0%)
    Peanut 0 (0%) 1 (100.0%)
1 n (%)

5.4 Dermatology

Characteristic PDC greater than or equal to 90
N = 183
1
PDC less than 90
N = 70
1
Age at date counseled

    Mean (SD) 48 (20) 41 (23)
    Median (Q1, Q3) 49 (33, 65) 43 (23, 61)
    Min, Max 5, 92 1, 85
Race

    White 138 (75.8%) 44 (24.2%)
    Black or African American 23 (59.0%) 16 (41.0%)
    Unknown 10 (58.8%) 7 (41.2%)
    Other 12 (80.0%) 3 (20.0%)
Sex

    Female 112 (72.7%) 42 (27.3%)
    Male 70 (71.4%) 28 (28.6%)
    Unknown 1 (100.0%) 0 (0%)
Medication

    Dupilumab 73 (65.8%) 38 (34.2%)
    Risankizumab-rzaa 32 (94.1%) 2 (5.88%)
    Adalimumab 15 (71.4%) 6 (28.6%)
    Secukinumab 13 (86.7%) 2 (13.3%)
    Apremilast 7 (50.0%) 7 (50.0%)
    Ixekizumab 7 (87.5%) 1 (12.5%)
    Tralokinumab-ldrm 4 (50.0%) 4 (50.0%)
    Upadacitinib 4 (66.7%) 2 (33.3%)
    Upadacitinib ER 5 (83.3%) 1 (16.7%)
    Ustekinumab 6 (100.0%) 0 (0%)
    Deucravacitinib 3 (75.0%) 1 (25.0%)
    Etanercept 3 (75.0%) 1 (25.0%)
    Guselkumab 4 (100.0%) 0 (0%)
    Ritlecitinib Tosylate 1 (33.3%) 2 (66.7%)
    Baricitinib 2 (100.0%) 0 (0%)
    Bexarotene 1 (50.0%) 1 (50.0%)
    Bimekizumab-bkzx 0 (0%) 2 (100.0%)
    Golimumab 1 (100.0%) 0 (0%)
    Lebrikizumab-lbkz 1 (100.0%) 0 (0%)
    Spesolimab-sbzo 1 (100.0%) 0 (0%)
1 n (%)
Characteristic At least 1 gap > 28 days
N = 49
1
No gaps > 28 days
N = 204
1
Age at date counseled

    Mean (SD) 40 (24) 48 (20)
    Median (Q1, Q3) 37 (23, 62) 49 (33, 64)
    Min, Max 1, 85 1, 92
Race

    White 28 (15.4%) 154 (84.6%)
    Black or African American 12 (30.8%) 27 (69.2%)
    Unknown 6 (35.3%) 11 (64.7%)
    Other 3 (20.0%) 12 (80.0%)
Sex

    Female 29 (18.8%) 125 (81.2%)
    Male 20 (20.4%) 78 (79.6%)
    Unknown 0 (0%) 1 (100.0%)
Medication

    Dupilumab 29 (26.1%) 82 (73.9%)
    Risankizumab-rzaa 1 (2.94%) 33 (97.1%)
    Adalimumab 5 (23.8%) 16 (76.2%)
    Secukinumab 2 (13.3%) 13 (86.7%)
    Apremilast 3 (21.4%) 11 (78.6%)
    Ixekizumab 1 (12.5%) 7 (87.5%)
    Tralokinumab-ldrm 3 (37.5%) 5 (62.5%)
    Upadacitinib 1 (16.7%) 5 (83.3%)
    Upadacitinib ER 1 (16.7%) 5 (83.3%)
    Ustekinumab 0 (0%) 6 (100.0%)
    Deucravacitinib 0 (0%) 4 (100.0%)
    Etanercept 0 (0%) 4 (100.0%)
    Guselkumab 0 (0%) 4 (100.0%)
    Ritlecitinib Tosylate 1 (33.3%) 2 (66.7%)
    Baricitinib 0 (0%) 2 (100.0%)
    Bexarotene 1 (50.0%) 1 (50.0%)
    Bimekizumab-bkzx 1 (50.0%) 1 (50.0%)
    Golimumab 0 (0%) 1 (100.0%)
    Lebrikizumab-lbkz 0 (0%) 1 (100.0%)
    Spesolimab-sbzo 0 (0%) 1 (100.0%)
1 n (%)

6 Pharmacist predictions

6.1 Neurology

Characteristic N = 1761
Would you be surprised if this patient discontinued this medication in the next 90 days?
    Yes 146 (83.0%)
    No 30 (17.0%)
Did this patient discontinue this medictaion?
    No 122 (69.3%)
    Yes 54 (30.7%)
Did this patient discontinue this medication within the next 90 days?
    No 140 (79.5%)
    Yes 36 (20.5%)
1 n (%)

Sensitivity: 15/36 = 0.42

Specificity: 125/140 = 0.89

PPV: 15/30 = 0.50

NPV: 125/146 = 0.86

Accuracy: 140/176 = 0.80

Characteristic Would be surprised (did not predict disc.)
N = 146
1
Would not be surprised (predicted disc.)
N = 30
1
Did this patient discontinue this medication within the next 90 days?

    No 125 (85.6%) 15 (50.0%)
    Yes 21 (14.4%) 15 (50.0%)
1 n (%)
Characteristic Would be surprised (did not predict disc.)
N = 21
1
Would not be surprised (predicted disc.)
N = 15
1
Reason for discontinuation

    Side effect or adverse drug event 10 (47.6%) 9 (60.0%)
    Patient Deceased 6 (28.6%) 1 (6.67%)
    No/suboptimal response to therapy or disease progression 3 (14.3%) 2 (13.3%)
    Patient decision 0 (0%) 2 (13.3%)
    Administration issues 1 (4.76%) 0 (0%)
    Disease state improvement 0 (0%) 1 (6.67%)
    Medication hold >60 days 1 (4.76%) 0 (0%)
1 n (%)
Characteristic Would be surprised (did not predict disc.)
N = 21
1
Would not be surprised (predicted disc.)
N = 15
1
Medication

    Droxidopa 7 (33.3%) 3 (20.0%)
    Pimavanserin 4 (19.0%) 2 (13.3%)
    Cannabidiol 2 (9.52%) 1 (6.67%)
    Edaravone 2 (9.52%) 1 (6.67%)
    Valbenazine 1 (4.76%) 2 (13.3%)
    Amantadine HCl ER 2 (9.52%) 0 (0%)
    Tetrabenazine 0 (0%) 2 (13.3%)
    Adalimumab 0 (0%) 1 (6.67%)
    Amantadine 0 (0%) 1 (6.67%)
    Deutetrabenazine 0 (0%) 1 (6.67%)
    Deutetrabenazine ER 1 (4.76%) 0 (0%)
    Eplontersen Sodium 1 (4.76%) 0 (0%)
    Istradefylline 0 (0%) 1 (6.67%)
    Tafamidis 1 (4.76%) 0 (0%)
1 n (%)

6.2 Oncology

Characteristic N N = 6431
Would you be surprised if this patient discontinued this medication in the next 90 days? 643
    Yes
555 (86.3%)
    No
88 (13.7%)
Did this patient discontinue this medictaion? 643
    No
388 (60.3%)
    Yes
255 (39.7%)
Did this patient discontinue this medication within the next 90 days? 643
    No
505 (78.5%)
    Yes
138 (21.5%)
1 n (%)

Sensitivity : 39/138 = 0.28

Specificity : 456/505 = 0.90

PPV: 39/88 = 0.44

NPV: 456/555 = 0.82

Accuracy: 495/643 = 0.77

Characteristic Would be surprised (did not predict disc.)
N = 555
1
Would not be surprised (predicted disc.)
N = 88
1
Did this patient discontinue this medication within the next 90 days?

    No 456 (82.2%) 49 (55.7%)
    Yes 99 (17.8%) 39 (44.3%)
1 n (%)
Characteristic Would be surprised (did not predict disc.)
N = 99
1
Would not be surprised (predicted disc.)
N = 39
1
Reason for discontinuation

    Side effect or adverse drug event 30 (30.3%) 11 (28.2%)
    No/suboptimal response to therapy or disease progression 31 (31.3%) 9 (23.1%)
    Patient Deceased 11 (11.1%) 8 (20.5%)
    Patient decision 7 (7.07%) 4 (10.3%)
    Full course of therapy completed 7 (7.07%) 2 (5.13%)
    Medication hold >60 days 6 (6.06%) 2 (5.13%)
    Provider decision 5 (5.05%) 0 (0%)
    Non-compliance 0 (0%) 3 (7.69%)
    Insurance mandate 1 (1.01%) 0 (0%)
    Lost to follow-up 1 (1.01%) 0 (0%)
1 n (%)
Characteristic Would be surprised (did not predict disc.)
N = 99
1
Would not be surprised (predicted disc.)
N = 39
1
Medication

    Capecitabine 7 (7.07%) 5 (12.8%)
    Venetoclax 8 (8.08%) 3 (7.69%)
    Eltrombopag Olamine 8 (8.08%) 0 (0%)
    Decitabine-Cedazuridine 5 (5.05%) 1 (2.56%)
    Abiraterone Acetate 5 (5.05%) 0 (0%)
    Lenvatinib 4 (4.04%) 1 (2.56%)
    Temozolomide 5 (5.05%) 0 (0%)
    Cabozantinib S-Malate 2 (2.02%) 2 (5.13%)
    Capivasertib 3 (3.03%) 1 (2.56%)
    PAZOPanib 2 (2.02%) 2 (5.13%)
    Relugolix 4 (4.04%) 0 (0%)
    Trifluridine-Tipiracil 2 (2.02%) 2 (5.13%)
    Zanubrutinib 4 (4.04%) 0 (0%)
    Adagrasib 1 (1.01%) 2 (5.13%)
    Asciminib HCl 3 (3.03%) 0 (0%)
    Cabozantinib 2 (2.02%) 1 (2.56%)
    Everolimus 1 (1.01%) 2 (5.13%)
    Imatinib Mesylate 1 (1.01%) 2 (5.13%)
    Darolutamide 1 (1.01%) 1 (2.56%)
    Dasatinib 2 (2.02%) 0 (0%)
    Erlotinib 2 (2.02%) 0 (0%)
    Ibrutinib 2 (2.02%) 0 (0%)
    Lomustine 1 (1.01%) 1 (2.56%)
    Olaparib 1 (1.01%) 1 (2.56%)
    Palbociclib 1 (1.01%) 1 (2.56%)
    Ribociclib 2 (2.02%) 0 (0%)
    SUNItinib Malate 0 (0%) 2 (5.13%)
    Abemaciclib 0 (0%) 1 (2.56%)
    Anakinra 1 (1.01%) 0 (0%)
    Apalutamide 0 (0%) 1 (2.56%)
    azaCITIDine 1 (1.01%) 0 (0%)
    Belzutifan 1 (1.01%) 0 (0%)
    Binimetinib 1 (1.01%) 0 (0%)
    cycloPHOSphamide 1 (1.01%) 0 (0%)
    Cyclophosphamide 0 (0%) 1 (2.56%)
    Dabrafenib Mesylate 0 (0%) 1 (2.56%)
    Deferasirox 1 (1.01%) 0 (0%)
    Deferiprone 1 (1.01%) 0 (0%)
    Encorafenib 1 (1.01%) 0 (0%)
    Enzalutamide 1 (1.01%) 0 (0%)
    Futibatinib (20 MG Daily Dose) 1 (1.01%) 0 (0%)
    Ivosidenib 1 (1.01%) 0 (0%)
    Lazertinib Mesylate 1 (1.01%) 0 (0%)
    Midostaurin 1 (1.01%) 0 (0%)
    Neratinib 0 (0%) 1 (2.56%)
    Nirogacestat 0 (0%) 1 (2.56%)
    Olutasidenib 1 (1.01%) 0 (0%)
    Osimertinib Mesylate 1 (1.01%) 0 (0%)
    PONATinib HCl 1 (1.01%) 0 (0%)
    Procarbazine HCl 1 (1.01%) 0 (0%)
    Ripretinib 1 (1.01%) 0 (0%)
    Selinexor (60 MG Once Weekly) 0 (0%) 1 (2.56%)
    Tivozanib HCl 1 (1.01%) 0 (0%)
    Trametinib Dimethyl Sulfoxide 0 (0%) 1 (2.56%)
    Tretinoin 0 (0%) 1 (2.56%)
    Tucatinib 1 (1.01%) 0 (0%)
1 n (%)

6.3 ASAP

Characteristic N = 2351
Would you be surprised if this patient had a PDC of less than 90 or dose interruptions totaling 28 days or more over the next 6 months?
    No 30 (12.8%)
    Yes 205 (87.2%)
Did the patient have a PDC of less than 90 or dose interruptions totaling 28 days or more over the 6 month follow-up?
    No 142 (60.4%)
    Yes 93 (39.6%)
Did the patient have a PDC of less than 90
    No 142 (60.4%)
    Yes 93 (39.6%)
Did the patient have at least 1 dose interruption totaling 28 days or more?
    No 191 (81.3%)
    Yes 44 (18.7%)
6 month PDC
    Mean (SD) 0.87 (0.16)
    Median (Q1, Q3) 0.93 (0.81, 0.99)
    Min, Max 0.19, 1.00
1 n (%)

Sensitivity : 14/93 = 0.15

Specificity : 126/142 = 0.89

PPV: 14/30 = 0.47

NPV: 126/205 = 0.61

Accuracy: 140/235 = 0.60

Characteristic Would be surprised (did not predict low adh.)
N = 205
1
Would not be surprised (predicted low adh.)
N = 30
1
Did the patient have a PDC of less than 90 or dose interruptions totaling 28 days or more over the 6 month follow-up?

    No 126 (61.5%) 16 (53.3%)
    Yes 79 (38.5%) 14 (46.7%)
1 n (%)
Characteristic PDC greater than or equal to 90
N = 142
1
PDC less than 90
N = 93
1
Would be surprised (did not predict low adh.)

    Yes 126 (88.7%) 79 (84.9%)
    No 16 (11.3%) 14 (15.1%)
1 n (%)
Characteristic PDC greater than or equal to 90
N = 142
1
PDC less than 90
N = 93
1
Medication

    Dupilumab 101 (71.1%) 66 (71.0%)
    Omalizumab 25 (17.6%) 17 (18.3%)
    Tezepelumab-ekko 8 (5.63%) 6 (6.45%)
    Mepolizumab 4 (2.82%) 2 (2.15%)
    Benralizumab 1 (0.70%) 2 (2.15%)
    Peanut Powder-dnfp Starter Pak 2 (1.41%) 0 (0%)
    Peanut 1 (0.70%) 0 (0%)
1 n (%)

6.4 Dermatology

Characteristic N = 2531
Would you be surprised if this patient had a PDC of less than 90 or dose interruptions totaling 28 days or more over the next 6 months?
    No 42 (16.6%)
    Yes 211 (83.4%)
Did the patient have a PDC of less than 90 or dose interruptions totaling 28 days or more over the 6 month follow-up?
    No 183 (72.3%)
    Yes 70 (27.7%)
Did the patient have a PDC of less than 90
    No 183 (72.3%)
    Yes 70 (27.7%)
Did the patient have at least 1 dose interruption totaling 28 days or more?
    No 204 (80.6%)
    Yes 49 (19.4%)
6 month PDC
    Mean (SD) 0.89 (0.16)
    Median (Q1, Q3) 0.97 (0.86, 1.00)
    Min, Max 0.31, 1.00
1 n (%)

Sensitivity : 15/70 = 0.21

Specificity : 156/183 = 0.85

PPV: 15/42 = 0.36

NPV: 156/211 = 0.74

Accuracy: 171/253 = 0.68

Characteristic Would be surprised (did not predict low adh.)
N = 211
1
Would not be surprised (predicted low adh.)
N = 42
1
Did the patient have a PDC of less than 90 or dose interruptions totaling 28 days or more over the 6 month follow-up?

    No 156 (73.9%) 27 (64.3%)
    Yes 55 (26.1%) 15 (35.7%)
1 n (%)
Characteristic PDC greater than or equal to 90
N = 183
1
PDC less than 90
N = 70
1
Would be surprised (did not predict low adh.)

    Yes 156 (85.2%) 55 (78.6%)
    No 27 (14.8%) 15 (21.4%)
1 n (%)
Characteristic PDC greater than or equal to 90
N = 183
1
PDC less than 90
N = 70
1
Medication

    Dupilumab 73 (39.9%) 38 (54.3%)
    Risankizumab-rzaa 32 (17.5%) 2 (2.86%)
    Adalimumab 15 (8.20%) 6 (8.57%)
    Secukinumab 13 (7.10%) 2 (2.86%)
    Apremilast 7 (3.83%) 7 (10.0%)
    Ixekizumab 7 (3.83%) 1 (1.43%)
    Tralokinumab-ldrm 4 (2.19%) 4 (5.71%)
    Upadacitinib 4 (2.19%) 2 (2.86%)
    Upadacitinib ER 5 (2.73%) 1 (1.43%)
    Ustekinumab 6 (3.28%) 0 (0%)
    Deucravacitinib 3 (1.64%) 1 (1.43%)
    Etanercept 3 (1.64%) 1 (1.43%)
    Guselkumab 4 (2.19%) 0 (0%)
    Ritlecitinib Tosylate 1 (0.55%) 2 (2.86%)
    Baricitinib 2 (1.09%) 0 (0%)
    Bexarotene 1 (0.55%) 1 (1.43%)
    Bimekizumab-bkzx 0 (0%) 2 (2.86%)
    Golimumab 1 (0.55%) 0 (0%)
    Lebrikizumab-lbkz 1 (0.55%) 0 (0%)
    Spesolimab-sbzo 1 (0.55%) 0 (0%)
1 n (%)